Physician profile
Jorge E Brunelle
NPI 1164443438
$18,743.06
in general payments reported to CMS, 2019-2025
29 companies · $2,105 in 2025
The $2,105 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,928 · 2020: $2,525 · 2021: $3,408 · 2022: $2,313 · 2023: $1,826 · 2024: $1,639 · 2025: $2,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,569.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,081.83 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,700.42 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $2,571.09 | 2019-2022 | |
| Novo Nordisk INC | $1,791.79 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $1,207.50 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $906.31 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $863.08 | 2020-2022 | |
| Abbvie INC. | $658.73 | 2020-2023 | Vraylar, Ubrelvy |
| Sanofi-Aventis U.S. LLC | $168.69 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $149.96 | 2019-2020 | |
| Antares Pharma, INC. | $132.84 | 2022 | |
| Medicure Pharma INC. | $70.09 | 2019 | |
| Arbor Pharmaceuticals, INC. | $56.75 | 2019-2021 | |
| Allergan, INC. | $45.24 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.29 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $41.32 | 2023-2025 | Seglentis, Zoryve |
| Dexcom, INC. | $41.05 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $33.89 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.99 | 2021 | |
| Ironwood Pharmaceuticals, INC | $23.49 | 2019 | |
| Eisai INC. | $18.77 | 2021 | |
| Evoke Pharma, INC. | $18.52 | 2025 | |
| Insulet Corporation | $17.03 | 2025 | Omnipod |
| Pfizer INC. | $14.78 | 2023 | |
| Corcept Therapeutics | $14.33 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $14.14 | 2021 | |
| Abbott Laboratories | $14.02 | 2019 | |
| Horizon Therapeutics Plc | $12.16 | 2022 | |
| Phathom Pharmaceuticals, INC. | $7.96 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Brunelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.